Table 1 Study population and clinical characteristics
Normal (n = 15) | DM (n = 18) | UAP (n = 18) | DM + UAP (n = 21) | |
|---|---|---|---|---|
Age(y) | 54.2 ± 11.4 | 56.2 ± 8.2 | 57.5 ± 10.5 | 55.3 ± 11.2 |
BMI(kg/m2) | 23.7 ± 1.3 | 24.2 ± 5.3 | 25.1 ± 3.6 | 24.6 ± 4.1 |
Hypertension(n) | 0 | 12* | 14* | 18* |
Diabetes duration(y) | --- | 3.9 ± 1.0 | --- | 4.1 ± 0.8 |
TC(mmol/l) | 3.1 ± 0.5 | 4.6 ± 1.4* | 4.7 ± 2.0* | 4.9 ± 1.8* |
LDL-C(mmol/l) | 1.6 ± 0.4 | 2.9 ± 0.7* | 3.1 ± 0.8* | 3.0 ± 1.5* |
HDL-C (mmol/l) | 1.2 ± 0.5 | 1.2 ± 0.7 | 1.1 ± 0.8 | 1.2 ± 0.6 |
TG (mmol/l) | 1.3 ± 0.7 | 2.2 ± 1.8* | 1.9 ± 1.5* | 2.0 ± 1.6* |
WBC(× 109) | 5.9 ± 0.9 | 7.2 ± 0.8 | 7.5 ± 0.8 | 6.8 ± 1.0 |
Fasting glycaemia(mg/ml) | 4.6 ± 0.7 | 8.5 ± 2.3#* | 5.2 ± 1.2 | 8.1 ± 1.7#* |
HbA1c(%) | 4.4 ± 0.88 | 8.4 ± 2.5#* | 5.1 ± 1.1 | 7.8 ± 1.8#* |
Medications | ||||
Statins | 0 | 16 | 18 | 20 |
Aspirin | 0 | 16 | 18 | 21 |
Fibrates | 0 | 1 | 0 | 1 |
ACE inhibitor/ARB | 0 | 13 | 14 | 17 |